Talking of kidney fibrosis, its enlightening to consider the...

Talking of kidney fibrosis, its enlightening to consider the number of people affected by chronic kidney disease (CKD). We know for instance that, according to the AdAlta presentation, greater than 490k people are impacted by IPF. According to the article Kidney fibrosis: from mechanisms to therapeutic medicines published in March 2023, CKD affects 10-14% of the global population.

We also learn from the article that kidney fibrosis is a hallmark manifestation in different progressive CKD and in particular that fibrosis occurs when wound healing is deregulated. Kidney damage is usually caused by pre-existing health conditions such as diabetes, high blood pressure and lupus but if unresolved, inevitably results in fibrosis due to the vicious cycle of repetitive injury, wound healing and the accumulation of excessive extracellular matrix proteins such as fibronectin and collagens.

How about treatment? According to the article Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products published in July 2022, there are presently no effective drugs for the treatment of renal fibrosis. There are of course treatments for CKD e.g. treating the underlying cause such as diabetes and resolving the inflammatory cycle, its just that - as far as I understand - there is a significant unmet need for antifibrotic treatments.

So now we can come back to the AdAlta May 2023 presentation and contemplate the significance of the statement that planning is underway for Phase 2 IV clinical trials in lung or kidney fibrosis. Who is pushing for Phase 2 in lung fibrosis and who is pushing for Phase 2 in kidney fibrosis. How do you decide, why don't we have both.